Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine-125 brachytherapy + TACE + lenvatinib + Tislelizumab in hepatocellular carcinoma with portal vein thrombosis (phase II, single-arm)
ChiCTR2500106171Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Objective response rate. Started Feb 2025; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106171.